WBDE(SZ:002082)2025-10-29 10:55Financial Performance - The company's revenue for Q3 2025 was CNY 439,154,394.07, representing a 36.51% increase compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 8,995,682.80, a decrease of 212.42% year-on-year[5]. - Total operating revenue for the current period was ¥1,017,706,438.36, a decrease of 5.1% compared to ¥1,074,491,139.98 in the previous period[24]. - The company's net profit for the current period is CNY 1,284,622.12, a significant decrease from CNY 36,246,556.95 in the previous period, representing a decline of approximately 96.45%[25]. - Operating profit for the current period is CNY 1,041,807.60, down from CNY 40,409,653.41 in the previous period, indicating a decrease of about 97.42%[25]. - The company's total comprehensive income for the current period is CNY 10,027,715.24, down from CNY 53,435,233.57 in the previous period, a decrease of approximately 81.24%[25]. - Basic and diluted earnings per share for the current period are both CNY 0.0100, a significant drop from CNY 0.0741 in the previous period[25]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was CNY 36,573,031.31, down 73.15% compared to the previous year[5]. - The company's cash and cash equivalents decreased from CNY 158,726,728.80 at the beginning of the period to CNY 83,070,795.97 at the end of the period, a decline of approximately 47.7%[20]. - Cash flow from operating activities for the current period is CNY 36,573,031.31, a decrease of 73.14% compared to CNY 136,224,725.34 in the previous period[26]. - Cash flow from investing activities shows a net outflow of CNY 287,768,022.83, worsening from a net outflow of CNY 193,233,025.70 in the previous period[27]. - Cash flow from financing activities resulted in a net inflow of CNY 179,098,407.90, compared to a net outflow of CNY 87,175,082.75 in the previous period, indicating a positive shift[27]. - The cash and cash equivalents at the end of the period amount to CNY 71,370,795.93, a slight decrease from CNY 73,766,560.85 in the previous period[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,541,970,797.02, an increase of 4.96% from the end of the previous year[5]. - Current assets totaled ¥1,742,675,531.54, a slight decrease from ¥1,803,320,380.71 in the previous period[21]. - Non-current assets increased to ¥2,799,295,265.48 from ¥2,524,076,699.82, reflecting a growth of 10.8%[21]. - Total liabilities rose to ¥1,775,399,359.75, compared to ¥1,570,954,359.63 in the previous period, indicating an increase of 13.0%[22]. - Total equity attributable to shareholders was ¥2,674,894,570.54, slightly up from ¥2,666,804,346.48[22]. - Long-term borrowings increased to ¥153,433,064.20 from ¥104,000,000.00, representing a growth of 47.5%[22]. - The company reported a decrease in short-term borrowings to ¥692,652,830.16 from ¥853,969,430.11, a reduction of 18.8%[22]. - Deferred tax assets increased to ¥150,623,375.37 from ¥134,444,446.98, showing a growth of 12.0%[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,415[12]. - The largest shareholder, Wanbangde Group Co., Ltd., holds 31.62% of the shares, with 153,150,000 shares pledged[12]. - The controlling shareholder and its concerted actors transferred a total of 60 million shares, accounting for 9.8089% of the company's total share capital, to a partnership on October 13, 2025[18]. - The company has not reported any changes in the participation of major shareholders in margin trading and securities lending activities[18]. Research and Development - Research and development expenses increased by 34.25% to CNY 71,623,824.70, reflecting higher investment in innovative drug development[10]. - Wanbangde Pharmaceutical obtained invention patents for compositions and formulations for treating Alzheimer's disease and skin photoaging, as well as for a disulfide cyclic peptide compound and its preparation methods[14]. - The company completed the first subject enrollment for the Phase II/III clinical trial of the new drug Huperzine A controlled-release tablets for treating mild to moderate Alzheimer's disease[15]. - The Phase II/III clinical trial received ethical approval from the Capital Medical University Xuanwu Hospital's ethics review committee, allowing collaboration with over 50 research institutions nationwide[17]. Government Subsidies - The company reported a significant increase in government subsidies, with CNY 1,719,364.84 recognized in the current period[7]. Revenue and Costs - The company experienced a decline in revenue and net profit primarily due to the failure to win bids for key products in national procurement[5]. - Total operating costs for the current period were ¥1,058,426,407.78, down 1.7% from ¥1,077,232,284.96 in the previous period[24]. - Operating costs included ¥689,033,168.53 in operating expenses, which increased from ¥638,499,206.00 in the previous period[24]. - Total revenue from sales of goods and services received in cash is CNY 809,415,293.19, down from CNY 1,058,777,535.36, reflecting a decline of approximately 23.51%[26]. Accounts and Inventory - Accounts receivable increased from CNY 681,903,501.91 to CNY 728,378,485.73, reflecting a growth of about 6.8%[20]. - Inventory rose from CNY 213,858,705.73 to CNY 248,924,311.07, indicating an increase of approximately 16.4%[20]. - Prepayments increased from CNY 335,327,642.24 to CNY 374,423,888.23, representing an increase of about 11.6%[20]. - Other receivables increased significantly from CNY 18,567,129.32 to CNY 51,554,753.86, a growth of approximately 177.5%[20].